LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

21.34 2.06

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

21.36

Métricas clave
By Trading Economics
Ingresos	-4.6M 52M
Ventas	5.1M 147M
P/B Media del Sector	12.994 77.256
Margen de beneficios	35.553
Empleados	181
EBITDA	5.9M 79M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+58.95% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-26M 2.6B
Apertura anterior	19.28
Cierre anterior	21.34

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

46 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 nov 2025, 21:06 UTC

Principales Movimientos del Mercado

JBS Down After Trump Calls for Probe into Meat-Packing Companies

8 nov 2025, 18:10 UTC

Ganancias

10 Defensive Stocks with Market-Beating Yields -- Barrons.com

8 nov 2025, 13:10 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov 2025, 12:00 UTC

Ganancias

Apple's iPhone Air Is a Marketing Win and a Sales Flop -- WSJ

8 nov 2025, 10:30 UTC

Ganancias

Why Car Insurers Are Under Pressure to Cut Rates -- Heard on the Street -- WSJ

8 nov 2025, 03:50 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov 2025, 03:41 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov 2025, 03:07 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov 2025, 22:36 UTC

Ganancias

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Ganancias

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov 2025, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 nov 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

7 nov 2025, 20:59 UTC

Ganancias

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov 2025, 20:26 UTC

Charlas de Mercado

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov 2025, 20:22 UTC

Ganancias

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov 2025, 20:04 UTC

Charlas de Mercado

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov 2025, 19:34 UTC

Charlas de Mercado

Gold Posts Small Gain for Week -- Market Talk

7 nov 2025, 19:31 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov 2025, 19:17 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov 2025, 19:09 UTC

Ganancias

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov 2025, 19:08 UTC

Ganancias

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov 2025, 18:31 UTC

Charlas de Mercado

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov 2025, 17:27 UTC

Charlas de Mercado

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

58.95% repunte

Estimación a 12 Meses

Media 34 USD 58.95%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

46 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.